How to Help Your Patients Find Kenalog In Stock: A Provider's Guide

When patients call your office after being turned away by their pharmacy, it puts your staff in a difficult position. During the 2026 Kenalog shortage, that scenario is happening constantly. This guide gives your clinical team a practical playbook for helping patients locate triamcinolone acetonide — whether that's through finding available stock, using the medfinder platform, or transitioning to a therapeutic equivalent.

Step 1: Verify In-Office or In-Clinic Supply First

Before directing patients elsewhere, check your own supply. Many rheumatology, orthopedic, dermatology, and allergy practices maintain their own vial stock purchased directly from medical distributors. Your in-house supply may have come from a different manufacturer or distribution channel than what the retail pharmacy is using. If you have stock, schedule the patient for an in-office injection.

If you're also running low, contact your medical distributor (McKesson, Cardinal Health, Medline, etc.) and ask about current allocation status. Switching distributors or working with your GPO may unlock access to manufacturer allocations.

Step 2: Direct Patients to medfinder

For patients who need to find a pharmacy that can fill their prescription independently, medfinder for providers is a practical resource. medfinder calls pharmacies near the patient to identify which ones have the medication in stock — then texts the patient the results. This removes the burden from your front desk staff and helps patients find what they need faster.

Consider printing or emailing patients a short instruction: "If you're having trouble filling your Kenalog or triamcinolone prescription at your pharmacy, visit medfinder.com and enter your medication, strength, and zip code. medfinder will contact pharmacies near you and text you the results."

Step 3: Recommend Specialty and Hospital Outpatient Pharmacies

Hospital outpatient pharmacies and specialty pharmacies often have access to manufacturer allocations through their institutional GPO contracts that are not available to retail chain pharmacies. When directing patients:

Identify 2–3 local hospital outpatient pharmacies that dispense to the public and provide this list to your front desk

Ask patients to request "triamcinolone acetonide injectable suspension 40 mg/mL" using the generic name, which may be stocked by a different manufacturer than brand Kenalog

Specialty compounding pharmacies with USP <797> sterile compounding capability can compound triamcinolone acetonide as a shortage alternative with a valid prescription

Step 4: Switch to a Therapeutic Alternative When Necessary

When Kenalog supply cannot be found in a reasonable timeframe, switching to a therapeutic alternative is clinically appropriate for most indications. Your recommended approach:

Intra-articular and IM use: Substitute methylprednisolone acetate (Depo-Medrol) mg-for-mg. Standard joint injection doses: 20–80 mg depending on joint size.

Intralesional (dermatology): Diluted Depo-Medrol (2.5–10 mg/mL) may be substituted for Kenalog-10 intralesional use for keloids, alopecia, and inflammatory plaques.

Systemic allergic/inflammatory conditions: IM methylprednisolone acetate 40–80 mg; for MS flares, IV methylprednisolone (Solu-Medrol) is the standard.

Managing Patient Expectations and Communication

Clear communication is essential during a shortage. Consider these best practices:

Post a notice in your waiting area and patient portal about the current shortage and what your practice is doing to address it

Train front desk staff to answer shortage questions with a scripted response rather than transferring every patient call to clinical staff

For patients with a scheduled injection appointment who may need a substitute: send a proactive message before they arrive to set expectations

Document shortage-related clinical decisions in the patient chart (reason for switch, alternative chosen, dose equivalency used)

Monitoring Patients Who Switch to Alternative Corticosteroids

When switching corticosteroids, consider the following:

Duration of action may differ between triamcinolone acetonide and the substitute. Methylprednisolone acetate has a slightly shorter duration; patients may report decreased duration of symptom relief.

Monitor diabetic patients closely — all injectable corticosteroids can cause transient hyperglycemia, but the degree and duration may vary slightly between agents.

Depo-Medrol does not contain benzyl alcohol; no benzyl alcohol sensitivity concerns during the switch.

Visit medfinder for providers to learn how to recommend medfinder to your patients during the shortage. For the clinical shortage overview, see: Kenalog Shortage: What Providers Need to Know in 2026.